Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims-Reference-Cited by-同舟云学术

Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims

Published:2023-08-10 Issue:9 Volume:39 Page:1237-1246
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Tse Jenny¹,Prajapati Girish²,Zhao Xiaohui¹^ORCID,Near Aimee M.¹,Kumar Princy N.³

Affiliation:

1. Real World Solutions, IQVIA, Durham, NC, USA

2. Merck & Co., Inc, Rahway, NJ, USA

3. Georgetown University Medical Center, Washington, DC, USA

Funder

Merck Sharp & Dohme LLC.

subsidiary of Merck & Co., Inc

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2023.2239661

Reference40 articles.

1. Centers for Disease Control and Prevention. HIV basics 2022. [updated June 21, 2022; cited 2022 September 29]. Available from: https://www.cdc.gov/hiv/basics/statistics.html.

2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

3. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

4. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

5. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study;Journal of Antimicrobial Chemotherapy;2024-01-24

2. A review of dolutegravir-associated weight gain and secondary metabolic comorbidities;SAGE Open Medicine;2024-01